Onapristone and Anastrozole in Refractory Estrogen and Progesterone Positive Endometrial Cancer
Status:
Recruiting
Trial end date:
2023-12-15
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of onapristone and anastrozole in treating patients
with hormone receptor positive endometrial cancer that has not responded to previous
treatment (refractory). Progesterone and estrogen are hormones that can cause the growth of
endometrial cancer cells. Onapristone blocks the use of progesterone by the tumor cells.
Anastrozole is a drug that blocks the production of estrogen in the body. Giving onapristone
with anastrozole may work better than anastrozole alone in treating patients with hormone
receptor positive endometrial cancer.